ArticleTherapeutics and clinical risk management2023

Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma.

Jinpeng Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.